Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MPL | P40238 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10248489 | 0.76 | ADORA3 (0.78) | ADORA3RXFP1MAPTMPLSMN1; SMN2 | |
| SCHEMBL2304853 | 0.75 | ADORA3 (0.74) | ADORA3RXFP1MAPTMPLSMN1; SMN2 | |
| SCHEMBL3313526 | 0.75 | ALDH1A1 (0.50) | ADORA3RXFP1DGAT1MAPTSMN1; SMN2 | |
| SCHEMBL22079803 | 0.75 | HCAR3 (0.52) | DGAT1 | |
| SCHEMBL6942413 | 0.74 | ADORA3 (1.00) | ADORA3RXFP1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL2355300 | 0.74 | MAPT (0.51) | ADORA3RXFP1MAPTSMN1; SMN2HTT | |
| SCHEMBL3312659 | 0.74 | ALDH1A1 (0.54) | RXFP1DGAT1MPLSMN1; SMN2NPC1 | |
| SCHEMBL3311847 | 0.73 | KDM4E (0.68) | RXFP1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL29530821 | 0.73 | ADORA3 (1.00) | ADORA3RXFP1MAPTMPLSMN1; SMN2 | |
| SCHEMBL9852328 | 0.71 | SMN1; SMN2 (0.73) | ADORA3RXFP1MAPTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350311-B1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | MADRIGAL PHARMACEUTICALS INC (US) | 2013-12-25 | — | — | EP | claimed |
| EP-2350311-B1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | MADRIGAL PHARMACEUTICALS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, MOGAT2 | ADORA3 1254/4885RXFP1 3724/4885DGAT1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.